Rigvir (ECHO-7) / Jiangsu Sinorda Biomedicine, Rigvir Group - LARVOL DELTA

Response to the letter to editor "Clarification on Rigvir's mechanism: Interpretation of CD55 inhibition in oncolytic therapy". (PubMed, Virology) - No abstract available

Journal • CD55

Clarification on Rigvir's mechanism: Misinterpretation of CD55 inhibition in oncolytic therapy. (PubMed, Virology) - No abstract available

Journal • CD55

Receptors and Host Factors for Enterovirus Infection: Implications for Cancer Therapy. (PubMed, Cancers (Basel)) - "It also summarizes the data on their expression in various types of cancer. By understanding how enteroviruses interact with specific cellular receptors, researchers can develop more effective regimens of treatment, offering hope for more targeted and efficient therapeutic strategies."

Journal • Review • Cardiovascular • Infectious Disease • Melanoma • Oncology • Solid Tumor

Breaking Barriers: Animal viruses as oncolytic and immunotherapeutic agents for human cancers. (PubMed, Virology) - "Notably, four leading contenders in this domain, Rigvir® in Latvia, T-VEC in the United States, H101 in China and Teserpaturev (DELYTACT®) in Japan, have earned approval for treating metastatic melanoma (Rigvir and T-VEC), nasopharyngeal carcinoma and malignant glioma, respectively...Furthermore, we provide a thorough examination of animal-derived oncolytic viruses, highlighting their respective strengths and limitations. Lastly, we explore the promising potential of leveraging animal viruses as potent oncolytic agents, offering new avenues for enhancing the efficacy and reach of human cancer therapeutics."

Journal • Review • Brain Cancer • CNS Tumor • Glioma • Melanoma • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

Oncolytic virus preclinical toxicology studies. (PubMed, J Appl Toxicol) - "This article summarizes the preclinical toxicology studies of the most well studied oncolytic viruses, including Oncorine, Talimogene laherparepvec, Cavatak, ONYX-015, teserpaturev, and Rigvir, a non-pathogenic ECHO-7 virus. It is concluded that oncolytic viruses have been shown to have low toxicity and high tolerability in preclinical toxicology studies."

Journal • Oncolytic virus • Preclinical • Review • Melanoma • Oncology • Solid Tumor

Comment on Hietanen et al. Cytolytic Properties and Genome Analysis of Rigvir Oncolytic Virotherapy Virus and Other Echovirus 7 Isolates. Viruses 2022, 14, 525. (PubMed, Viruses) - "In a recent article published in Viruses by Hietanen et al. [...]."

Journal • Oncolytic virus

Reply to Alberts, P. Comment on "Hietanen et al. Cytolytic Properties and Genome Analysis of Rigvir Oncolytic Virotherapy Virus and Other Echovirus 7 Isolates. Viruses 2022, 14, 525". (PubMed, Viruses) - "Our work focused on comparing the cellular effects of Rigvir to other echovirus 7 isolates, because originally Rigvir is also an echovirus 7 isolate [...]."

Journal • Oncolytic virus

Stage IIA Skin Melanoma Treatment With ECHO-7 Oncolytic Virus Rigvir. (PubMed, Perm J) - "This case report illustrates an early treatment approach. Neoadjuvant treatment for early-stage melanoma is gaining more interest in both scientific and medical communities; therefore, the authors believe it is relevant to share their observations."

Journal • Oncolytic virus • Melanoma • Oncology • Solid Tumor

Cytolytic Properties and Genome Analysis of Rigvir Oncolytic Virotherapy Virus and Other Echovirus 7 Isolates. (PubMed, Viruses) - "Thus, we conclude that Rigvir's claim of being an effective treatment against multiple different cancers is not warranted under the evidence presented here. Bioinformatic analyses do not reveal a clear mechanism that could elucidate Rigvir's function at a molecular level, and cell infectivity tests do not show a discernable difference in either the oncolytic or oncotropic effect between Rigvir and other clinical E7 isolates used in the study."

Journal • Oncolytic virus • Infectious Disease • Oncology